Date: 2015-10-14
Type of information: Nomination
Compound:
Company: CEVEC Pharmaceuticals (Germany)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 14, 2015, CEVEC Pharmaceuticals, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, announced the expansion and reorganization of its management team. Dr. Nico Scheer will join the Company as Vice President Business Development Glycoproteins as of November 1, 2015. Dr. Scheer will be responsible for CEVEC\'s growth strategy in the Company\'s CAP®Go activities.Prior to joining CEVEC, Dr. Scheer served in different leading management positions within Artemis Pharmaceuticals GmbH, TaconicArtemis GmbH and Taconic Biosciences GmbH - most recently as Director Business Development and Head of tADMET portfolio. Dr. Scheer adds more than 10 years of experience in business development, portfolio and project management, plus licensing and partnering activities in the life science industry as well as a strong scientific background in drug metabolism, molecular biology, and in vitro technologies. He holds a PhD in Molecular Developmental Biology and a PMI certified Project Management Professional (PMP). Dr. Hartmut Tintrup, currently Chief Business Officer, moves to the position of Vice President Business Development Gene Therapy and Viruses in which he will be responsible for the growth of CEVEC\'s CAP®GT business. Both will be reporting to CEO Frank Ubags.
Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH, commented, \"Following our focus on glycoproteins and gene therapy vectors in May 2015 and the subsequent successful co-operations, we have increased our overall headcount by 40% and attracted competent, talented people in the scientific, quality assurance and regulatory business fields. We are experiencing an exponentially increasing demand for our CAP®Go portfolio in the field of glycoproteins and for our CAP(R)GT technology for the industrial scale production of gene therapy vectors. With this strengthening and restructuring of the management team, we are now well placed to further accelerate the growth of our Company.\"
CEVEC Pharmaceuticals has developed two expression platforms, CAP®Go and CAP®GT. The CAP®Go platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The CAP®GT expression platform provides a regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities and show a broad viral propagation spectrum including lentivirus, adenovirus and adeno-associated virus. In addition, the Company provides contract manufacturing for the GMP production in CAP®Go and CAP®GT cells.
Financial terms:
Latest news:
